GlassScriptPhysician profile
Daya Sharma
NPI 1871527937
$69,192.09
in general payments reported to CMS, 2019-2025
85 companies · $4,423 in 2025
The $4,423 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,241 · 2020: $9,047 · 2021: $8,899 · 2022: $19K · 2023: $12K · 2024: $6,723 · 2025: $4,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $3,634 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,975 · Consulting Fee: $2,892 · Honoraria: $1,700 · Long Term Medical Supply Or Device Loan: $997 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,427.41 |
| Travel and Lodging | $3,633.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,975.00 |
| Consulting Fee | $2,892.00 |
| Honoraria | $1,700.00 |
| Long Term Medical Supply Or Device Loan | $997.00 |
| Education | $206.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $9,694.03 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $8,892.87 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Pfizer INC. | $8,805.02 | 2019-2025 | |
| Exelixis INC. | $8,732.62 | 2019-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $5,019.52 | 2020-2025 | Ojjaara, Shingrix, Blenrep |
| Pharmacosmos Therapeutics INC. | $3,053.28 | 2022-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $2,626.94 | 2019-2023 | Rezlidhia, Tavalisse |
| Novartis Pharmaceuticals Corporation | $2,379.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,606.79 | 2019-2025 | Opdivo, Eliquis, Krazati |
| Daiichi Sankyo INC. | $1,594.10 | 2022-2025 | Enhertu, Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $1,343.47 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,288.12 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $883.38 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Celgene Corporation | $779.00 | 2019-2025 | Reblozyl, Pomalyst |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $654.62 | 2019-2025 | Kyprolis, Lumakras, Nplate |
| Genzyme Corporation | $600.52 | 2019-2024 | |
| Abbvie INC. | $552.74 | 2019-2025 | Venclexta |
| Seagen INC. | $500.07 | 2019-2023 | Tukysa, Padcev |
| Lilly USA, LLC | $463.87 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $426.34 | 2019-2025 | |
| Taiho Oncology, INC. | $417.33 | 2019-2025 | |
| Genentech USA, INC. | $412.08 | 2019-2023 | Lunsumio, Polivy, Gazyva |
| Pharmacyclics LLC, An Abbvie Company | $395.02 | 2019-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $382.86 | 2019-2025 | |
| Cardinal Health 110 LLC | $375.00 | 2020-2025 | |
| Astellas Pharma US INC | $357.43 | 2019-2025 | Padcev, Xtandi |
| Sanofi-Aventis U.S. LLC | $350.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $346.92 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $336.96 | 2019-2025 | |
| Tg Therapeutics, INC. | $326.46 | 2021 | |
| Athenex Pharmaceutical Division, LLC | $325.00 | 2020 | |
| Global Blood Therapeutics, INC. | $278.53 | 2020-2022 | |
| Puma Biotechnology, INC. | $262.66 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $221.61 | 2022-2024 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.34 | 2019-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Clovis Oncology, INC. | $198.35 | 2019-2021 | |
| Coherus Oncology, INC. | $187.12 | 2020-2025 | Loqtorzi |
| Tersera Therapeutics LLC | $153.35 | 2022-2025 | Xermelo, Zoladex |
| Mirati Therapeutics, INC. | $143.09 | 2023-2024 | Krazati |
| Amneal Pharmaceuticals LLC | $142.00 | 2025 | |
| Beigene USA, INC. | $138.13 | 2020-2023 | Brukinsa |
| Spectrum Pharmaceuticals INC. | $131.23 | 2023-2024 | Rolvedon |
| Sobi, INC | $131.13 | 2022-2025 | |
| Boston Scientific Corporation | $112.56 | 2022-2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Kite Pharma, INC. | $100.21 | 2023-2024 | Yescarta |
| Gilead Sciences, INC. | $96.36 | 2022-2025 | Trodelvy |
| Azurity Pharmaceuticals, INC. | $93.72 | 2024-2025 | Danziten, Vivimusta |
| Foundation Medicine, INC. | $88.52 | 2020-2023 | |
| G1 Therapeutics, INC. | $87.93 | 2022-2023 | Cosela |
| Karyopharm Therapeutics INC. | $74.18 | 2022-2025 | Xpovio |
| Morphosys, US INC. | $69.50 | 2022-2023 | Monjuvi |
| Janssen Pharmaceuticals, INC | $67.65 | 2019-2020 | |
| Genmab U.S., INC. | $62.52 | 2023-2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $61.50 | 2019-2024 | Somatuline Depot, Onivyde |
| Array Biopharma INC | $60.81 | 2021-2025 | Lorbrena, Mektovi, Braftovi |
| Beone Medicines USA, INC. | $54.66 | 2025 | Brukinsa, Tevimbra |
| Pharmaessentia USA Corporation | $51.77 | 2022 | |
| Heron Therapeutics, INC. | $50.44 | 2019-2022 | |
| Kyowa Kirin, INC. | $49.86 | 2025 | |
| Novocure INC. | $46.70 | 2019-2025 | Optune Lua (Novottf-200t) |
| Octapharma USA, INC. | $45.76 | 2022-2024 | Panzyga |
| Eusa Pharma (US) LLC | $43.48 | 2022 | |
| Geron Corporation | $42.99 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $42.23 | 2021-2023 | Qinlock |
| Accord Healthcare, INC. | $41.73 | 2024 | |
| Myriad Genetic Laboratories, INC. | $40.36 | 2021 | |
| Myovant Sciences INC. | $35.50 | 2022 | |
| Agios Pharmaceuticals, INC. | $29.92 | 2025 | Pyrukynd |
| Tempus Ai, INC | $28.66 | 2024 | Xt Cdx |
| Stemline Therapeutics INC. | $28.41 | 2023 | Orserdu |
| Mylan Institutional INC. | $28.33 | 2023 | Hulio |
| Recordati_rare_diseases_inc. | $27.94 | 2024 | Sylvant |
| Immunogen, INC. | $25.37 | 2023 | Elahere |
| Tesaro, INC. | $23.89 | 2019 | |
| Epizyme, INC. | $23.04 | 2022 | |
| Blueprint Medicines Corporation | $20.77 | 2022 | |
| Btg International INC. | $20.65 | 2020 | |
| Blue Earth Diagnostics | $20.14 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.83 | 2025 | Givlaari |
| Lundbeck LLC | $18.31 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.75 | 2019 | |
| Breas Medical, INC. | $15.49 | 2025 | Vivo 45 Ls |
| Amag Pharmaceuticals, INC. | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daya Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.